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Abstract
Tumor neovascularization is a highly complex process including multiple steps. Understanding this process, especially the
initial stage, has been limited by the difficulties of real-time visualizing the neovascularization embedded in tumor tissues in
living animal models. In the present study, we have established a xenograft model in zebrafish by implanting mammalian
tumor cells into the perivitelline space of 48 hours old Tg(Flk1:EGFP) transgenic zebrafish embryos. With this model, we
dynamically visualized the process of tumor neovascularization, with unprecedented high-resolution, including new sprouts
from the host vessels and the origination from VEGFR2
+ individual endothelial cells. Moreover, we quantified their
contributions during the formation of vascular network in tumor. Real-time observations revealed that angiogenic sprouts
in tumors preferred to connect each other to form endothelial loops, and more and more endothelial loops accumulated
into the irregular and chaotic vascular network. The over-expression of VEGF165 in tumor cells significantly affected the
vascularization in xenografts, not only the number and size of neo-vessels but the abnormalities of tumor vascular
architecture. The specific inhibitor of VEGFR2, SU5416, significantly inhibited the vascularization and the growth of
melanoma xenografts, but had little affects to normal vessels in zebrafish. Thus, this zebrafish/tumor xenograft model not
only provides a unique window to investigate the earliest events of tumoral neoangiogenesis, but is sensitive to be used as
an experimental platform to rapidly and visually evaluate functions of angiogenic-related genes. Finally, it also offers an
efficient and cost-effective means for the rapid evaluation of anti-angiogenic chemicals.
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Introduction
Tumorgenic neovascularization is established as essential for
sustaining tumor progression and metastatic spread, in response to
interactions between tumor cells and endothelial cells, growth
factors, and extracellular matrix components [1–5]. Without
angiogenesis, most tumors will not progress to a clinically relevant
size nor will they metastasize to distant organs through the blood
stream. After the triggering of ‘angiogenic switch’ at the early stage
of tumor growth, tumors vascular network will be established
gradually. Vasculatures in tumors often are architecturally
different from their normal counterparts — they are haphazardly
constructed, irregularly shaped and tortuous [6–8]. As a result,
blood flow is irregularly in tumor vessels, moving much slowly and
sometimes even oscillating [9]. The structural and functional
abnormalities in tumor vessels produce the unique tumor
microenvironment — hypoxic and lacking nutrients, owning to
poor blood perfusion, high interstitial fluid pressure, acidosis, fast
growth and metabolic rates of malignant tissues [10], and finally
promote tumor cells to invade adjacent healthy tissue and leading
to metastasis—the major cause for failure in cancer treatment
[11,12]. The process of tumorgenic neovascularization is so
complex that it has not been fully understood, although various
signals that trigger this switch have been discovered. It is necessary
to develop novel high-resolution experimental systems to further
understand the abnormalities and underlying mechanisms of
tumor vasculatures, and for the development of antiangiogenic
chemicals.
An ideal experimental system for investigation of neovascular-
ization in tumors, at least in our opinion, should posses these
characteristics: the high-resolution on single-cell level, appropriate
for real-time observation and quantitative analysis, can display the
critical process of the transition from avascular to vascular stage,
can be used for anti-angiogenesis drug discovery, easy to establish
and manipulate in numerous animals, low costs for research. Some
experimental models have been established in rodents and chick
embryo to investigate the angiogenic biology and for the screening
of proangiogenic and antiangiogenic compounds. The technolog-
ical developments of skinfold chamber and intravital microscopy
have deepened the understanding to tumor-induced angiogenesis
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model or technology has its advantages and disadvantages [13,14],
none of them simultaneously fulfill all requirements mentioned
above.
Recently, the zebrafish has been developed as a promising
experimental model for cancer research because of strikingly
similar molecular and histopathological features between fish and
human [15–17]. This animal model has many advantages in
cancer research field comparing to other vertebrate model systems,
such as transparency, ease of experimentation, feasibility to in vivo
manipulation, and so on. Several studies have reported the
approaches to investigate tumor growth, metastasis and interac-
tions between tumor cells and neighboring vessels [18–21]. After
transplantation of human tumor cell lines into zebrafish embryos,
the neovascularization induced by tumor xenografts was observed
[18,19]. However, the tumor xenografts are embedded in the
zebrafish tissues, it’s difficult to clearly and dynamically monitor
tumor growth and neovascularization within tumor tissues. In the
present study, we described a novel experimental procedure to
establish the tumor xenograft model in Tg(Flk1:EGFP) transgenic
zebrafish, in which individual green endothelial cells can be clearly
distinguished from red tumor cells. The process of neovasulariza-
tion in tumors can be dynamically visualized and quantitatively
analyzed on single-cell level. Moreover, this model is sensitive
enough to respond to the alternation of angiogenic gene in tumor
cells and small molecular antiangiogenic chemicals.
Materials and Methods
Cell and Cell Culture
B16 mouse melanoma cells, CT26 mouse colon cancer cells and
human embryonic kidney cells HEK293 were obtained from
American Type Culture Collection (ATCC, Manassas, VA). All
cells were cultured at 37uCi n5 %C O 2 in DMEM supplemented
with 10% fetal bovine serum. The stable transfection was
generated with pCMV-DsRed-express (Clontech, USA) by using
Lipofectamine 2000 reagent (Invitrogen, USA), followed by G418
selection. Clones expressing red fluorescence were isolated for
further selection. Selected red fluorescence-labeled cells were
cultured at 37uCi n5 %C O 2 in DMEM supplemented with 10%
fetal bovine serum and 200 mg/ml selective agent.
Ethics Statement
All animal work have been approved by Sichuan Animal Care
and Use Committee and conducted according to relevant
guidelines. The Permit Number is SYXK (Chuan) 2008-119.
Zebrafish Husbandry and Cell microinjection
Tg(flk1: EGFP) zebrafish were bred and maintained normally
(temperature, 28uC; pH 7.2–7.4; 14 hr on and 10 hr off light
cycle). Wild type or red fluorescence-labeled cells were harvested
at a concentration of 1610
7 cells/ml. This mixture was loaded
into a borosilicate glass needle pulled by a Flaming/Brown
micropipette puller (Narishige, Japan, PN-30). 5,10 nanoliters
suspension containing about 50–100 cells were implanted into
each zebrafish embryo through the perivitelline space in a single
injection by using an electronically regulated air-pressure micro-
injector (Harvard Apparatus, NY, PL1-90). After injection,
zebrafish were washed once with fish water and examined for
the presence of fluorescent cells. For each implantation, about 50
fish were selected and transferred to 6-well plate containing 2 ml
of fresh fish water and subsequently documented photographically.
Fish water was changed daily, and larva that more than 5 days old
were fed twice a day with grinded brine shrimp and maintained
under normal fish husbandry conditions.
Imaging
Living zebrafish embryos were anesthetized by 0.003% tricaine
and embedded in a dorsal, ventral, or lateral orientation in 3%
methylcellulose. Digital micrographs were taken with a Zeiss
Imager.Z1 fluorescence microscope (Carl Zeiss Microimaging
Inc., Germany) equipped with an AxioCam MRc5 digital CCD
camera (Carl Zeiss Microimaging Inc., Germany). Whole animal
images were taken with a Zeiss Stemi 2000-C stereomicroscope
with the AxioCam MRc5 digital CCD camera (Carl Zeiss
Microimaging Inc., Germany). All images were taken in the same
focal plane in brightfield and intransmitted light passing through
RFP or GFP filters. Excitation was 488 nm for GFP, 561 nm for
DsRed. To clearly imaging all vessels within xenograft models,
0.5–2 mm step z-stacks (5126512 focal planes, 50–200 mmi n
depth) were acquired by using 106(ZEISS, Plan-Neofluar) or
206(ZEISS, Plan-Neofluar) objectives. Images capture, processing
and adjustment were performed with ZEISS Axiovision rel.4.8
software.
Pharmacological Treatment of Fish with SU5416
SU5416 (Sigma) was added directly into the fish water at a final
concentration of 2 mM. DMSO (Sigma) was used as a vehicle
control. Animals were maintained in 2 ml fish water that was
changed daily.
Quantitative analysis of neovascularization in tumor
xenografts
Measurement was done on the zebrafish photos taken with a
Zeiss Imager.Z1 fluorescence microscope (Carl Zeiss Microima-
ging Inc., Germany) equipped with an AxioCam MRc5 digital
CCD camera (Carl Zeiss Microimaging Inc., Germany). The
tumor size, vessel length and vessel diameter were quantified by
Axiovision Rel 4.8 software (Carl Zeiss Microimaging Inc.,
Germany).
MTT assay
The growth rate of B16 cells in vitro was determined by the 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT; Sigma, St. Louis, MO, USA) colorimetric assay. Briefly,
about 3000 cells were cultured in a 96-well plate at a volume of
100 mL of medium/well and incubated over night. The cells were
incubated in complete medium containing 0, 1, 2 mM SU5416,
respectively. After 48 h of incubation, the medium was aspirated
and 20 mL of 5 mg/mL MTT was added per well and incubated
at 37uC for 4 h; then supernatant fluid was removed, and 150 mL
of dimethyl sulfoxide (DMSO) was added per well. Spectrometric
absorbance at 490 nm was measured using a microplate reader.
The cell survival rate was assessed as percent cell viability in terms
of non-treated control cells.
Western blotting
B16 cells were planted in six-well plate (about 5610
5 per well)
and transfected pcDNA3.1- VEGF165 or pcDNA3.1 vector with
Lipofectamine 2000 (Invitrogen) as the standard protocol. Forty-
eight hours after transfection, western blot analysis was performed
[22] to test the expression of VEGF165 in B16 cells. Briefly, total
lysate proteins of B16, B16-vector, B16-VEGF165 cells were
separated on SDS- SDS-polyacrylamide gels and transferred to a
PVDF membrane. After transfer, the membrane was blocked with
5% nonfat dry milk in PBS with 0.5% Tween 20 to block
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actin) were identified by incubating with monoclonal antibody in
TBS with 0.1% Tween and 5% nonfat milk (blotting buffer)
overnight at 4uC. b-actin (Santa Cruz) was detected as the internal
control. After several washing, PVDF membrane was incubated
with horseradish peroxidase–conjugated secondary antibody
(1:8,000) in blotting buffer at room temperature for 45 minutes.
Then membranes were washed and protein antibody complexes
were visualized by chemiluminescent detection using SuperSignal
West Pico Chemilumenescent Substrate (Pierce).
Histology Analysis
To evaluate the tumor growth on zebrafish embryos, the
xenografted zebrafish was embedded in tissue freezing medium
(OCT). Frozen zebrafish was sectioned to 8 mm thickness, and
hematoxylin and eosin staining was performed as standard
protocol.
Statistical Analysis
Data was assayed by unpaired student’s t test using SPSS18.0
statistical analysis software. A level of P,0.05 was regarded as
statistically significant.
Results
The establishment of tumor xenograft models in
zebrafish
Red fluorescence-labeled malignant cells (murine colon carci-
noma CT26 and melanoma B16 cells) were implanted into the
perivitelline space of 48 hpf (hours post fertilization)
Tg(flk1:EGFP) transgenic zebrafish embryos (50–100 cells/em-
bryo). Non-tumorigenic HEK 293 cells were injected as the
control (Fig. 1A,B). Five days after cells injection, solid tumors
(350–450 mm in diameter) were established in 100% of CT26 and
B16 cells implants (n=50). The formed neoplasia with hemi-
spheric morphology obviously protruded from the abdomen of the
transgenic zebrafish (Fig. 1B). Dual fluorescent living images
demonstrated a plenty of green neovessels existed in red tumor
cells (Fig. 1B). On the contrary, non-malignant HEK 293 cells
failed to form any obvious tumors on the fish abdomen and no
endothelial cells penetration was observed as well (Fig. 1B). The
HE staining of neoplasia tissues further confirmed the establish-
ment of B16 and CT26 tumor in the zebrafish embryos (Fig. 1B).
Meanwhile, the growth rate of the xenografted tumor and the
number of tumor-induced neovessels were quantified, showing the
significant difference between malignant cells (B16 and CT26) and
non-malignant HEK 293 cells (P,0.001) (Fig. 1C,D).
The quantitative analysis of different neovascularization
modes
Through careful investigating the formation of the initiation
vascular network, we found there were two distinct neovascular-
ization processes occurred in B16 xenogarfts (Fig. 2 and 3). First, in
all B16 neoplasia (Fig. 2A), the initial neo-angiogenic sprouts firstly
projecting from the preexisting host dilated vessels on 2nd day
after cell injection (Fig. 2B, 2dpi panel). With the growth of B16
tumor (Fig. 2A), more neo-vessels were induced into tumor tissue
and tumor vascular architectures were established gradually
(Fig. 2A,B). On the 6th day post injection, the obvious tumor
mass could observed in zebrafish (Fig. 2A, 6dpi panel), in which
filled with a chaotic plexus of newly formed angiogenic sprouts
(Fig. 2B, 6dpi panel). Second, in most B16 neoplasia (about 70%),
Figure 1. The establishment of mammalian tumor xenograft models in zebrafish. Red fluorescence-labeled malignant tumor cells (murine
colon carcinoma CT26 and melanoma B16 cells) and non-tumorigenic HEK 293 cells were implanted into the abdominal perivitelline space (A,
indicated by arrow) of 48 hpf Tg(flk1:EGFP) transgenic zebrafish embryos (50–100 cells/embryo). When tumors (B, red) reached 350–450 mmi n
diameter when filled with neo-vessels (B, green), the neoplasia were isolated and analyzed by H&E staining (B). The growth rate of xenografted
tumors (C) and the number of tumor-induced neovessels (D) were analyzed quantitatively. * indicates the significant difference. Scale bar, 100 mm.
doi:10.1371/journal.pone.0021768.g001
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the central region of B16 tumor xenografts (Fig. 3A,B). Dynamic
real-time imaging revealed that the length of these individual
VEGFR2+ endothelial cells increased gradually with the progres-
sion of tumor neovascularization and finally fused with adjacent
growing neoangiogenic sprouts (Fig. 3C). Quantitative analysis
indicated that angiogenic sprouts derived from host vessels had a
major contribution to the initial formation of tumor vascular
network, while those individual endothelial cells within micro-
tumors have a relative less contribution to that (1264%, n=12)
(Fig. 3D).
The formation process of chaotic vascular network in B16
xenograft
Vascular network in malignant tumor uses to be highly
irregular, heterogenic and tortuous. In order to illustrate how
angiogenic sprouts grow into a complex and chaotic vascular
network, the neovascularization in B16 melanoma xenografts in
Tg(flk1:EGFP) transgenic zebrafish were dynamically imaged
(Fig. 4 A–E). The observations showed that the initial endothelial
cells that had penetrated into tumor tissue preferred to connect
each other to form endothelial loops rather than continuously
growing forward in tumor tissues (Fig. 4 A,B). This imaging possess
unprecedented high-resolution that pseudopodia protruding from
individual endothelial cells could be clearly displayed (Fig. 4 A).
With the growth of the tumor, more and more endothelial loops
assembled into a complex vascular network (Fig. 4C, angiogenic
sprouts were indicated by arrows, the formed endothelial loops
were indicated by crosses). In addition, endothelial loops were
diverse significantly in size and shape (Fig. 4D). Consequently, the
final vasculatures in tumors, comprising of diverse numerous
endothelial loops, look like highly irregular and chaotic comparing
to that in normal tissues.
Significant effects of angiogenic gene VEGF165 to the
neoangiogenesis in tumor xenografts
To evaluate whether this xenograft model can be used for the
investigation of angiogenic-relative genes, B16 cells over-express-
ing VEGF165 (Fig. 5A) were implanted into zebrafish. Non-
transfected and vector transfected B16 cells were used as controls.
On the 6th day post injection, in VEGF165 over-expressed B16
melanoma xenografts, in addition to more neovessels were
induced into (Fig. 5B), vessel length, vessel branch points and
vessel diameter also significantly increased based on the
quantitative analysis, when compared to control B16 xenografts
(Fig. 5B–E).
Significant inhibition of tumoral neovascularization by
SU5416
To address the application of this xenograft model for the
screening of chemical drug candidates, we investigated the effects
of SU5416, a widely used VEGFR2 specific inhibitor, on the
angiogenesis in B16 melanoma xenografts in zebrafish. The results
showed that 2 mM SU5416 significantly inhibited the neovascu-
larization (Fig. 6A) and tumor growth (Fig. 6B) of B16 xenografts
on 5 dpi, however, had little effects to the normal vascular vessels
of zebrafish (Fig. 6C). The quantitative analysis further confirmed
the inhibiting effects of SU5416 to neovascularization (Fig. 6D)
and tumor growth (Fig. 6E). To exclude the toxicity of SU5416
(2 mM) to B16 cells, we tested the proliferation rate of B16 cells
Figure 2. Dynamical observations of aniogenesis in B16 xenografts. The established microtumors (A, 3dpi and 6dpi panels) in zebrafish
larvae are indicated by arrowheads. Neo-vessels are indicated by arrows (B).
doi:10.1371/journal.pone.0021768.g002
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inhibition (Fig. 6F).
Discussion
Anti-angiognesis represents a promising strategy for cancer
therapy. Zebrafish has several unique features including develop
rapidly ex vivo, transparent body during the first week, inexpensive
to maintain, breed in large numbers, and can be maintained in
small volumes of water [23]. These characteristics have made
zebrafish become an attractive model for cancer research and
angiogenesis assay.
Previous studies have shown that transplantation of human
tumor cell lines into zebrafish embryos induces increased
vasculature, providing a model to investigate tumor xenografts
induced neovascularization [18,19]. However, tumor xenografts in
these models are embedded in the zebrafish tissues, resulting in the
difficulties of real-time monitoring tumor growth and direct
observations of neovascularization within tumor tissues on single-
cell level. Moreover, hosts (zebrafish) must be sacrificed to
quantitatively analyze the neovascularization in xenografts. In
the present study, we have described a novel experimental
procedure to establish a tumor xenograft model for angiogenesis
assay in Tg(flk:EGFP) transgenic zebrafish. Comparing to known
models in rodent, chicken embyos and zebrafish, this one has some
unique characteristics: first, the protocol is much easier and
simpler, only need the direct injection of tumor cell suspension into
zebrafish and no other reagents are included, such as Matrigel
[18,19]. Second, tumor xenografts in zebrafish grow locally in
perivitelline space and finally form an isolated hemispherical
neoplsia protruding out of the zebrafish body. So, the shape of
xenografts is regular and obvious during the whole growth process,
the tumor growth can be readily measured for quantitative
analysis without the interference from the host tissues. Third, the
sharp visual contrast between green vascular endothelial cells and
red tumor cells within isolated and transparent xenografts provides
unprecedented clarity allowing the clear observation of neovascu-
larization at single-cell level. Fourth, no surgical operations are
Figure 3. The participation of individual VEGFR2+ endothelial cells to the initial formation of tumor vascular network. Individual
VEGFR2+ endothelial cells located at the center of B16 xenograft (indicated by arrow, A). The region in white dotted box was magnified in B. With the
tumor growth (C), individual endothelial cells (arrows) increased its length and fused with angiogenic sprouts (arrowheads). (D) Histogram represents
(n=12, p,0.05) the percentage of endothelial columns that originated from the individual ECs or the angiogenic sprouts. Scale bar, 100 mm (A, C) or
50 mm (B).
doi:10.1371/journal.pone.0021768.g003
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it is very appropriate for dynamic observations of neovasculariza-
tion during tumor growth. Fifth, there are no any neovascular-
ization in the region where tumor cells were implanted throughout
the experimental period in the absence of inducement from tumor
cells. Thus, almost all newly formed ectopic microvessels induced
by tumor xenografts can be unequivocally identified and
quantified under fluorescent microscope with unprecedented
clarity. Consequently, with this model we have clearly investigated
the initiation of vascularization within tumor tissues, and recorded
the participation of VEGFR2
+ individual endothelial cells.
Furthermore, we have quantified the contributions of classical
angiogenesis and VEGFR2
+ individual endothelial cells to the
formation of tumor vascular network. Our dynamic observations
showed that these VEGFR2+ individual endothelial cells were able
to increase their length over time and then fuse with the sprouting
tumor vasculatures. Their behaviors are similar to endothelial
precursor cells (EPCs) that have been previously described on
mammalian tumor model [24,25]. To our knowledge, at least, this
is the first time that clearly in vivo observed the dynamic process of
EPC-like endothelial cells participating in the formation of tumor
neovaculature at the initial stage of tumor growth.
The neovasculature in tumor is chaotic, of heterogeneous angio-
architecture, has large caliber vessels and sluggish blood flow [26].
However, the formation process of this complex vascular network
in vivo is still not clear. The tumor xenografts in the present study
initiated from a very limited number of cells (as low as 50–100 cells
per embryo), thus can mimic the earliest stages of tumor
Figure 4. The formation of chaotic microvascular network in B16 xenografts. (A) The interconnection of initial endothelial cells that had
penetrated into tumor tissue. (B) Schematic diagram showing the forming and formed endothelial loops. (C) The dynamic process of more and more
endothelial loops assembling into a complex vascular network. Angiogenic sprouts were indicated by arrows, the formed endothelial loops were
indicated by crosses. (D) Endothelial loops varied significantly in size and shape. The B16 xenograft is indicated by arrow (E). Scale bars, 200 mm.
doi:10.1371/journal.pone.0021768.g004
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high-resolution, we found endothelial cells that had penetrated
into tumor tissue preferred to connect each other to form
endothelial loops rather than continuously growing forward
straightly. These endothelial loops were varied significantly in
size and shape. The final vasculatures in tumors comprise of
diverse numerous endothelial loops, thus look like highly irregular
and chaotic comparing to that in normal tissues. These in vivo
observations about the formation process of tumor vasculatures
provide a reasonable explanation on cellular level to why the
architecture of neovasculatures in tumor always is chaotic and
heterogeneous. Also, these results provided a good clue to the
Figure 5. The over-expression of VEGF in B16 cells promoting tumor neovascularization. (A) Weston-blot revealed the expression of
VEGF165 at 48 hours post transfection. (B) The tumor-induced neo-vessels were greatly affected by the over-expression of VEGF165 in B16 cells, (C–E)
Statistical graphs revealed the changes of vessel length (C), vessel branch points (D) and mean diameters of neovessels (E). Scale bar, 100 mm.
doi:10.1371/journal.pone.0021768.g005
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further investigated in the future work.
The development of vascular system in zebrafish embryo shows
strong similarity to that in other vertebrates [20,21]. Robust
angiogenic responses can be triggered in zebraifsh when human
and murine tumorigenic cell lines were injected into 2-day-old
zebrafish embryos [18]. Furthermore, the zebrafish tumor
xenograft models have shown the capacity to discriminate between
highly and poorly angiogenic tumor cells in previous [18] and our
present studies, indicating zebrafish tumor xenograft models can
be used to investigate the mechanisms of cancer neovasculariza-
tion. Previous studies [18,19] have shown that tumorigenic FGF2-
overexpressing mouse aortic endothelial cells (FGF2-T-MAE)
triggered the rapid formation of a new microvasculature when
grafted close to the developing subintestinal vessels (SIV) of
zebrafish embryos at 48 h postfertilization, whereas parental MAE
cell grafts only limited change the SIV architecture. In the present
study, we showed that VEGF-overexpressing B16 cells induced
stronger angiogenic response (in vessel length, vessel branch points
and vessel diameter) within tumor xenografts. Obviously, com-
paring to other often used angiogenesis assays, such as rodents
cornea or a chick embryo chorioallantoic membrane [27–29],
zebrafish xenograft model has unique characteristics: first, this is
an in vivo model but assay can be very easily finished as an in vitro
manner. Second, the usage of Tg(flk1: EGFP) make neo-vessels
within tumor tissues can be easily observed and quantified.
Therefore, through injecting distinct cells, in which target genes
have been over-expressed or down-regulated into zebrafish
embryos as the approach described in our present study, we can
readily identify angiogenesis-relative genes underlying angiogenic
process.
In contrast to the mouse, the zebrafish is a more economical
and efficient model species for the cost-quality and high-
throughput in vivo screening of small-molecule anti-tumor
compounds, in that: 1) zebrafish embryo shows great permeability
to small-molecule chemical compounds [30]. 2) The maintenance
cost of zebrafish is less than 1% that of mice [31]. 3) A large
number of tumor xenograft in zebrafish embryos can be easily
established. A trained researcher is capable to inject tumor cells
into 100–200 embryos within one hour. 4) Zebrafish with tumor
xenograft can be maintained in six- or 96-well plates, so the
systemic in vivo screening can be performed with minimal amounts
Figure 6. The small-molecular inhibitor of VEGFR2 inhibiting the tumor growth and neovascularization. (A–C) The imaging showed the
obvious blockage of the specific inhibitor of VEGFR2, SU5416 (2 mM), to the neovascularization (A), tumor growth (B), and normal vascular vessels of
zebrafish (C). (D,E) The quantitative analysis of the inhibiting effects of SU5416 to neovascularization (D) and tumor growth (E). (F) The result of MTT
assay for B16 cells that treated by SU5416 for 48 hours in vitro at a concentration of 0, 1, 2 mM. Scale bar, 100 mm.
doi:10.1371/journal.pone.0021768.g006
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compounds can be easily performed. Importantly, the zebrafish
tumor model can investigated simultaneously the toxicity of tested
compounds to normal vessels and embryo development. We used
a well-known chemical compound SU5416, the specific inhibitor
of VEGFR2, as the model drug to validate the application of this
xenograft. 2 mM SU5416 significantly inhibited the angiogenesis
within B16 xenografts on 5 dpi, but had little effects to the normal
vascular vessels of zebrafish and the embryo development. The
experiment was performed in a 96-well plate (100 mL per well), so
only a small quantity of chemical inhibitor was used. The whole
experimental process is similar to the tests on cultured cells in vitro,
but that we obtain are in vivo data on the whole animal level.
Taken together, the zebrafish tumor xenograft model estab-
lished in the present study represents a promising in vivo platform
for tumor angiogenesis investigation and anti-tumor drug
discovery.
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